US2012295867A1PendingUtilityA1

Method and pharmaceutical to treat spinal discs

Assignee: EEK BJORN C JPriority: Oct 31, 2000Filed: Mar 21, 2012Published: Nov 22, 2012
Est. expiryOct 31, 2020(expired)· nominal 20-yr term from priority
Inventors:Bjorn Eek
A61P 25/00A61K 31/737A61K 47/20A61K 31/7004A61K 31/7008A61K 47/26A61K 47/42A61K 47/24A61K 31/445A61K 9/0019A61P 23/00A61K 31/726A61K 47/36A61K 47/02
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for reducing chronic pain caused by a disrupted spinal disc are described. In one method, a solution is injected into the disc. The solution includes chondroitin sulphate, glucosamine HCl, and dextrose. The solution may optionally include dimethyl sulfoxide and/or an anesthetic such as bupivicaine.

Claims

exact text as granted — not AI-modified
1 - 36 . (canceled) 
     
     
         37 . A method of reducing chronic pain caused by a disrupted spinal disc comprising he step of injecting a solution into said disc, the solution comprising:
 chondroitin sulphate;   glucosamine HCl ; and   dextrose.   
     
     
         38 . The method of  claim 37 , further comprising dimethyl sulfoxide. 
     
     
         39 . The method of  claim 37 , wherein the solution further comprises an anesthetic. 
     
     
         40 . The method of  claim 39 , wherein the anesthetic is bupivicaine. 
     
     
         41 . A method of treating an internal disc disruption comprising the step of injecting a solution into said disc, the solution comprising:
 chondroitin sulphate;   glucosamine HCl; and   dextrose.   
     
     
         42 . The method of  claim 41 , further comprising dimethyl sulfoxide. 
     
     
         43 . The method of  claim 41 , wherein the solution further comprises an anesthetic. 
     
     
         44 . The method of  claim 43 , wherein the anesthetic is bupivicaine.

Join the waitlist — get patent alerts

Track US2012295867A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.